Have you noticed how in recent years, IT companies have been increasingly venturing into the health sector? Software and electronics companies are developing innovative solutions such as electronic health records systems, telemedicine platforms, wearable health devices, and AI-driven diagnostic tools.
Conversely, pharmaceutical companies are undergoing a digital transformation to adapt to changing market dynamics and optimize their operations. They are adopting digital tools for drug discovery, clinical trials, and supply chain management to accelerate the development and distribution of new drugs. Big data analytics, machine learning, and computational modeling are being harnessed to identify potential drug candidates, predict patient responses, and expedite the research process.
A whole new industry sector is emerging at the intersection of technology, information science, and healthcare. This convergence brings about novel challenges and opportunities that require innovative approaches to protecting intellectual property rights.
To address those needs, the two established Swiss IP firms P&TS SA and Pharma Patents International AG (PPI) recently presented the CrossTechIP® initiative, focusing on the synergies between the traditional life sciences and the digital technologies. CrossTechIP® appears as a convincing solution for companies involved in hybrid activities in the field of digital health. We indeed offer tailor-made services to provide the most accurate and personalized analysis. The outcome of our attendance at the SwissMedTech day confirms that it responds to a need and that CrossTechIp® can address a large variety of problematics, from a very specific issue to an holistic solution.
More on www.crosstechip.com
